Annals of Surgical Oncology

, Volume 18, Issue 4, pp 961–969

A Phase 2 Study of 99mTc-Tilmanocept in the Detection of Sentinel Lymph Nodes in Melanoma and Breast Cancer

  • Stanley P. L. Leong
  • Julian Kim
  • Merrick Ross
  • Mark Faries
  • Charles R. Scoggins
  • Wendy L. Rich Metz
  • Frederick O. Cope
  • Richard C. Orahood
Melanomas

DOI: 10.1245/s10434-010-1524-z

Cite this article as:
Leong, S.P.L., Kim, J., Ross, M. et al. Ann Surg Oncol (2011) 18: 961. doi:10.1245/s10434-010-1524-z

Abstract

Background

Several 99mTc-labeled agents that are not approved by the U.S. Food and Drug Administration are used for lymphatic mapping. A new low-molecular-weight mannose receptor–based, reticuloendothelial cell-directed, 99mTc-labeled lymphatic imaging agent, 99mTc-tilmanocept, was used for lymphatic mapping of sentinel lymph nodes (SLNs) from patients with primary breast cancer or melanoma malignancies. This novel molecular species provides the basis for potentially enhanced SLN mapping reliability.

Methods

In a prospectively planned, open-label phase 2 clinical study, 99mTc-tilmanocept was injected into breast cancer and cutaneous melanoma patients before intraoperative lymphatic mapping. Injection technique, preoperative lymphoscintigraphy (LS), and intraoperative lymphatic mapping with a handheld gamma detection probe were performed by investigators per standard practice.

Results

Seventy-eight patients underwent 99mTc-tilmanocept injection and were evaluated (47 melanoma, 31 breast cancer). For those whom LS was performed (55 patients, 70.5%), a 99mTc-tilmanocept hot spot was identified in 94.5% of LS patients before surgery. Intraoperatively, 99mTc-tilmanocept identified at least one regional SLN in 75 (96.2%) of 78 patients: 46 (97.9%) of 47 in melanoma and 29 (93.5%) of 31 in breast cancer cases. Tissue specificity of 99mTc-tilmanocept for lymph nodes was 100%, displaying 95.1% mapping sensitivity by localizing in 173 of 182 nodes removed during surgery. The overall proportion of 99mTc-tilmanocept-identified nodes that contained metastatic disease was 13.7%. Five procedure-related serious adverse events occurred, none related to 99mTc-tilmanocept.

Conclusions

Our results demonstrate the safety and efficacy of 99mTc-tilmanocept for use in intraoperative lymphatic mapping. The high intraoperative localization and lymph node specificity of 99mTc-tilmanocept and the identification of metastatic disease within the nodes suggest SLNs are effectively identified by this novel mannose receptor–targeted molecule.

Copyright information

© Society of Surgical Oncology 2011

Authors and Affiliations

  • Stanley P. L. Leong
    • 1
  • Julian Kim
    • 2
  • Merrick Ross
    • 3
  • Mark Faries
    • 4
  • Charles R. Scoggins
    • 5
  • Wendy L. Rich Metz
    • 6
  • Frederick O. Cope
    • 6
  • Richard C. Orahood
    • 6
  1. 1.California Pacific Medical Center and Sutter Pacific Medical Foundation and Research InstituteUniversity of CaliforniaSan FranciscoUSA
  2. 2.University Hospitals Case Medical CenterClevelandUSA
  3. 3.Department of Surgical OncologyM. D. Anderson Cancer CenterHoustonUSA
  4. 4.John Wayne Cancer InstituteSanta MonicaUSA
  5. 5.Department of SurgeryUniversity of LouisvilleLouisvilleUSA
  6. 6.Department of Clinical ResearchNeoprobe CorporationDublinUSA